Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Plus Therapeutics, retaining the price target of $1.50.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jason McCarthy has given his Buy rating due to a combination of factors tied to Plus Therapeutics’ advancing pipeline and strengthened balance sheet. The company ended the year with sufficient cash and subsequently raised additional equity, which McCarthy believes should fund operations into 2027, supporting key value-driving clinical and commercial milestones.
He highlights the ongoing ReSPECT-LM and ReSPECT-GBM Phase 2 studies of Reyobiq, both of which are progressing toward potentially pivotal or registration-enabling designs, backed by encouraging prior survival data and FDA feedback. In parallel, he views the growing adoption and payer coverage of the CNSide assay—along with clear 2026 commercialization targets—as an emerging revenue opportunity that complements the therapeutic programs and supports a favorable risk‑reward profile for PSTV shares.
In another report released on February 26, Lake Street also maintained a Buy rating on the stock with a $2.00 price target.